Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

The Market Herald04-23

ASX-listed and WA-based Emyria Limited (ASX:EMD) has announced its successful receipt of commitments for $2.3M in funding to expand its clinical services intended to treat medication-resistant PTSD ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429135643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-23 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429135643","market":"us","top_or_hot":-1,"title":"Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M","media":"The Market Herald","content":"<div>\n<p>ASX-listed and WA-based Emyria Limited (ASX:EMD) has announced its successful receipt of commitments for $2.3M in funding to expand its clinical services intended to treat medication-resistant PTSD ...</p>\n\n<a href=\"https://themarketonline.com.au/emyria-locks-in-2-3m-to-progress-mdma-research-with-chair-adding-0-3m-2024-04-23/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-23 10:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/emyria-locks-in-2-3m-to-progress-mdma-research-with-chair-adding-0-3m-2024-04-23/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ASX-listed and WA-based Emyria Limited (ASX:EMD) has announced its successful receipt of commitments for $2.3M in funding to expand its clinical services intended to treat medication-resistant PTSD ...</p>\n\n<a href=\"https://themarketonline.com.au/emyria-locks-in-2-3m-to-progress-mdma-research-with-chair-adding-0-3m-2024-04-23/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://themarketonline.com.au/emyria-locks-in-2-3m-to-progress-mdma-research-with-chair-adding-0-3m-2024-04-23/","article_id":"2429135643","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429135643","pubTimestamp":1713840120,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"ASX-listed and WA-based Emyria Limited  has announced its successful receipt of commitments for $2.3M in funding to expand its clinical services intended to treat medication-resistant PTSD with MDMA and similar compounds.Capital raisings of any kind aren’t typically smiled upon by shareholders, reflected in today’s -1.8% decline of the EMD share price to 5.5c in lunchtime trades.The company highlighted on Tuesday that its Chair, Greg Hutchinson, has subscribed for $0.3M. Total C-suite participation clocked in at $320,000.All in all, the company seeks to use the funds to expand its clinical services. Those clinical services are, ultimately, the product of a partnership with University of Western Australia  chemists.Those chemists have developed a range of ‘MDMA-like compounds’ for use in treating patients with PTSD who have not responded well to traditional methodologies for that condition.The emerging field of science – if you want to use the word ’emerging’ – has long been of interest","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK7113":"保健护理机构","BK7502":"大麻概念","EMD.AU":"Emyria Ltd"},"translate_title":"Emyria锁定230万美元推进MDMA研究Chair增加30万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMD.AU":1},"content_text":"ASX-listed and WA-based Emyria Limited (ASX:EMD) has announced its successful receipt of commitments for $2.3M in funding to expand its clinical services intended to treat medication-resistant PTSD with MDMA and similar compounds.\nCapital raisings of any kind aren’t typically smiled upon by shareholders, reflected in today’s -1.8% decline of the EMD share price to 5.5c in lunchtime trades.\nThe company highlighted on Tuesday that its Chair, Greg Hutchinson, has subscribed for $0.3M. Total C-suite participation clocked in at $320,000.\nAll in all, the company seeks to use the funds to expand its clinical services. Those clinical services are, ultimately, the product of a partnership with University of Western Australia (UWA) chemists.\nThose chemists have developed a range of ‘MDMA-like compounds’ for use in treating patients with PTSD who have not responded well to traditional methodologies for that condition.\nThe emerging field of science – if you want to use the word ’emerging’ – has long been of interest to bona fide mental health professionals, as well as more spiritualistic types of individuals.\nThe basic premise, in layman’s terms, is that pscyhoactive drugs like MDMA may allow one to ‘unlock’ parts of their inner psyche that would otherwise be inaccessible to the participating patient.\nMuch similar research exists where looking at ‘magic mushroom’ compound psilocybin, and the latter half of the 20th century had no shortage of studies using LSD for similar means.\nOverall efficacy of using such drugs for complex mental health conditions remains mixed, with some reports glowing and others finding the premise is, on the whole, unrealistic.\nStill, strong interest persists within the medical and mental health academic communities, as well as in the broader community.\nThe company recently launched its ‘Empax centre’ – a play on the word empathy, which MDMA is supposedly meant to enhance in individuals – and today’s announced funding will go towards this endeavour before operating overhead.\n“We are embarking on an exciting phase of growth with our newly opened Empax Centre. I am profoundly optimistic about the impact our work will have on mental health,” Emyria chair Greg Hutchinson said. \n“I am confident that the strategic use of these funds will significantly advance our mission, set new standards in care, and ultimately transform lives.”\nFor those who are enthusiastic about the notion of using MDMA to treat mental health, it can be easy for excitement to cause confusion.\nThis journalist is aware many people presume MDMA will be prescribed on a take-home basis, but this is far from reality.\nAny such trials are conducted in a guided therapy session and dosages are typically conservative. Participation is often expensive and insurance can be a nightmare. \nThat’s before getting into still-unknown questions about what, exactly, makes some people respond well to the treatments over others.\nThe long-term efficacy of MDMA treatments are also less widely reported than evidence that initial outcomes may improve, in some people.\nEMD shares last traded at 5.5cps.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429135643"}